William Blair Reaffirms Outperform Rating for Verve Therapeutics (NASDAQ:VERV)

Verve Therapeutics (NASDAQ:VERV)‘s stock had its “outperform” rating reissued by equities research analysts at William Blair in a note issued to investors on Friday,RTT News reports.

VERV has been the topic of several other research reports. HC Wainwright dropped their price target on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Royal Bank of Canada dropped their price target on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Finally, Canaccord Genuity Group increased their price target on shares of Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $25.75.

Verve Therapeutics Stock Down 7.0 %

VERV stock opened at $7.28 on Friday. Verve Therapeutics has a 12-month low of $4.30 and a 12-month high of $19.34. The company has a market cap of $616.32 million, a price-to-earnings ratio of -2.96 and a beta of 1.74. The company has a 50 day moving average of $6.80 and a two-hundred day moving average of $5.96.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC grew its position in Verve Therapeutics by 189.7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock worth $34,000 after purchasing an additional 3,964 shares during the last quarter. IFP Advisors Inc grew its position in Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock worth $47,000 after purchasing an additional 8,237 shares during the last quarter. Creative Planning acquired a new stake in Verve Therapeutics in the 3rd quarter worth $50,000. BNP Paribas Financial Markets acquired a new stake in Verve Therapeutics in the 4th quarter worth $50,000. Finally, PFG Investments LLC acquired a new stake in Verve Therapeutics in the 3rd quarter worth $53,000. 97.11% of the stock is currently owned by institutional investors and hedge funds.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.